Core Viewpoint - The report details the fundraising activities and the management of raised funds by Seres Group, highlighting the amounts raised, their usage, and the compliance with regulations [1][2][3][4][5]. Fundraising Overview - The company raised a total of RMB 7,129,999,969.18 through a non-public offering of A-shares, with a net amount of RMB 7,058,556,088.13 after deducting issuance costs [1]. - As of June 30, 2025, the company has utilized RMB 256,377.43 million from the 2021 non-public offering for investment projects, with a remaining balance of RMB 2,505.26 million [1][3]. Fund Management - The company has established a fundraising management system to ensure compliance and protect investor interests, with the latest revision approved on October 27, 2023 [1][2]. - Fundraising accounts are managed under specific agreements with banks and sponsors, ensuring dedicated use of the funds for intended projects [2][3]. Fund Usage - The company has used RMB 458,180.02 million for investment projects, including RMB 10,000 million from idle funds temporarily supplementing working capital [3][4]. - No projects have been terminated or transferred during the reporting period, and there are no instances of mismanagement of funds [4][5]. Project Performance - The report indicates that certain projects, such as the SERES intelligent connected new energy vehicle development, do not directly generate economic benefits but are essential for future growth [3][4]. - The company has not encountered any delays in project progress or significant changes in project feasibility during the reporting period [4][5].

Core Viewpoint - The document outlines the management and usage guidelines for funds raised by Shenzhen Guangfeng Technology Co., Ltd, emphasizing the importance of compliance with relevant laws and regulations to protect shareholder interests and ensure efficient use of raised funds [1][2]. Fund Management and Usage - The company must establish internal control systems for the management, usage, and supervision of raised funds, including clear approval authority and decision-making processes [2][3]. - Raised funds must be stored in dedicated accounts, and any excess funds should also be managed within these accounts [5][6]. - A tripartite supervision agreement must be signed with the underwriter and the bank holding the funds within one month of the funds being received [3][4]. Fund Usage Requirements - The company is required to use raised funds according to the plans outlined in the issuance application documents and must report any significant deviations [10][12]. - Funds should primarily be used for main business operations and cannot be used for financial investments or to benefit related parties improperly [11][12]. - Any temporary use of idle funds for cash management must be approved by the board and disclosed [7][8]. Changes in Fund Usage - Any changes in the intended use of raised funds must be approved by the board and disclosed to shareholders [20][21]. - The company must provide detailed reasons for any changes in project implementation or funding allocation [22][23]. Reporting and Supervision - The company must regularly disclose the actual usage of raised funds and any discrepancies from the planned usage [24][25]. - An annual audit by an accounting firm is required to verify the management and usage of raised funds, with findings disclosed in the annual report [15][27].

Fundraising Overview - The company raised a total of RMB 119 million by issuing 68 million shares at RMB 17.50 per share, with a net amount of RMB 106.25 million after deducting issuance costs of RMB 12.75 million [1] - As of June 30, 2025, the company has utilized RMB 99.23 million of the raised funds, with a remaining balance of RMB 5,072.57 [1][2] Fund Management - The company has established a dedicated account for managing the raised funds, ensuring compliance with relevant regulations and protecting investor interests [1] - The company has signed a tripartite supervision agreement with its sponsor and the bank managing the funds, which is functioning normally as of June 30, 2025 [1] Fund Utilization - The company has not replaced any of the raised funds with its own prior investments [1] - A total of RMB 11.6 million of temporarily idle funds has been approved for cash management, with investments in safe and liquid financial products [1] - The company has not used idle funds to temporarily supplement working capital during the reporting period [1][2] Project Status - The company has completed the projects "New Generation Laser Display Product R&D and Industrialization" and "Headquarters R&D Center Project," reallocating surplus funds to permanent working capital [1][3] - The expected output from the "New Generation Laser Display Product R&D" project is 135,000 units per year, but actual production has been affected by market demand and supply chain issues [3] Compliance and Reporting - The company has adhered to all relevant laws and regulations regarding the use and disclosure of raised funds, with no significant issues reported [1][2] - The company has not experienced any abnormal situations regarding the investment projects funded by the raised capital [2]

| 证券代码：603388 证券简称：*ST 元成 公告编号：2025-097 | | | --- | --- | | 元成环境股份有限公司 | | | 关于公司 2025 年半年度募集资金存放与实际使用情况的专项报告 | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | 据中国证券监督管理委员会《上市公司募集资金监管规则》（证监会公告 | | | 〔2025〕10 号）、《上海证券交易所上市公司自律监管指引第 1 号——规范运 | | | 5 月修订）》以及《上海证券交易所上市公司自律监管指南第 1 号 | 作（2025 年 | | ——公告格式（2025 年 4 月修订）》的相关规定及元成环境股份有限公司（以 | | | 下简称"公司"）《募集资金使用管理办法》等有关法律、法规和规范性文件的 | | | 规定，现将公司 2025 年半年度募集资金存放与实际使用情况说明如下： | | | 一、募集资金基本情况 | | | (一)实际募集资金金额和资金到账时间 | | | 经中国证券监督管理委员会 ...

三生国健药业（上海）股份有限公司 募集资金管理制度 第一章 总则 第六条 保荐机构或者独立财务顾问应当按照《证券发行上市保荐业务管理 办法》 《上市规则》、本制度的规定，对公司募集资金的管理和使用履行持续督导 职责，公司应当予以配合。 第一条 为了规范三生国健药业（上海）股份有限公司（以下简称"公司"） 募集资金的管理和使用，保护投资者的权益，依照《中华人民共和国公司法》 （以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司募 集资金监管规则》等有关法律法规及规范性文件的规定，结合公司实际情况，特 制定本制度。 第二条 本制度适用于公司通过发行股票或者其他具有股权性质的证券，向 投资者募集并用于特定用途的资金监管，但不包括公司为实施股权激励计划募集 的资金监管。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能力和创新 ...

Core Viewpoint - The company has completed the commitment of fundraising investment for certain projects and plans to permanently supplement its working capital with the remaining funds, which is expected to enhance the efficiency of fund utilization and support its operational activities [1][6][7]. Fundraising Basic Situation - The company was approved to publicly issue 61,621,142 shares at a price of RMB 28.18 per share, raising a total of RMB 1,736,483,781.56, with the net amount after deducting underwriting fees and other expenses being RMB 1,736,483,781.56 [1][2]. Fundraising Investment Plan - The company has outlined its fundraising investment plan in accordance with its prospectus and subsequent announcements, detailing the allocation of funds to various projects, including new drug development and digital factory construction [2][3]. Fund Usage and Surplus Situation - As of August 29, 2025, the company has completed the committed investments for the "new drug development project for autoimmune and ophthalmic diseases" and the "innovation antibody drug industrialization and digital factory construction project," with other fundraising projects concluded [3][4]. Reasons for Fund Surplus - The surplus in fundraising is attributed to effective cost control and management during project execution, leading to lower investment costs. Additionally, the company has generated investment income from temporarily idle funds [4][5]. Surplus Fund Usage Plan - The company plans to permanently supplement its working capital with RMB 7,029.08 million of surplus funds, which will be used for daily operational activities to enhance cash flow and economic efficiency [5][6]. Approval Procedures - The board of directors and the supervisory board have approved the plan to use surplus funds, confirming that it aligns with the company's development strategy and does not harm the interests of shareholders [6][7].

Summary of Key Points Core Viewpoint The report provides a detailed account of the fundraising activities and the management of the raised funds by Sanofi Guojian Pharmaceutical (Shanghai) Co., Ltd. for the first half of 2025, highlighting the total amount raised, its allocation, and adjustments made to investment projects. Fundraising Overview - The company raised a total of RMB 1,736,483,781.56 through the issuance of 61,621,142 shares at RMB 28.18 per share, with a net amount of RMB 1,634,428,187.64 after deducting fees [1][2][3] - As of June 30, 2025, the balance of the special account for raised funds was RMB 81,117,314.56 [1][2] Fund Management - The company established a dedicated fund management system in compliance with relevant regulations, ensuring that funds are stored in special accounts and used exclusively for designated projects [1][2] - The company has signed tripartite and quadripartite agreements with banks and sponsors to clarify rights and obligations regarding fund management [1][2] Actual Use of Funds - The funds were primarily allocated to projects related to the company's main business and to supplement working capital [2][3] - As of June 30, 2025, the total amount used from the raised funds was RMB 1,494,204,365.06, with additional interest income contributing to the fund balance [1][2] Adjustments to Investment Projects - The company has made adjustments to the investment amounts for various projects, including reducing the budget for the "Antibody Drug Production New Project" from RMB 65 million to RMB 35 million and increasing the budget for the "Self-immune and Eye Disease Antibody Drug R&D Project" from RMB 15 million to RMB 25 million [4][5][6] - The adjustments were approved in meetings and are aimed at optimizing the use of raised funds while maintaining the total investment commitment [4][5][6] Temporary Use of Idle Funds - The company has temporarily supplemented working capital with surplus funds from various projects, amounting to RMB 66,628,200, with a repayment period not exceeding 12 months [3][4][5] - The company has also approved the use of idle funds for cash management, with a limit of RMB 30 million for a period of 12 months [3][4][5] Compliance and Reporting - The company has confirmed that all disclosed information regarding the use of raised funds is accurate and timely, with no violations in fund usage [5][6] - The report includes a detailed comparison of the actual use of funds against the planned allocations, ensuring transparency and accountability [5][6]

Core Viewpoint - Sangfor Biopharmaceuticals (Shanghai) Co., Ltd. has completed the investment commitments for its antibody drug research projects and has decided to permanently supplement its working capital with the remaining funds from these projects [1][6]. Fundraising Overview - The company was approved to publicly issue 61,621,142 shares at a price of RMB 28.18 per share, raising a total of RMB 1,736,483,781.56, with a net amount of RMB 1,634,428,187.64 after deducting fees [1][2]. Investment Projects - The main projects funded include: - New drug research for autoimmune and ophthalmic disease antibodies - Industrialization of innovative antibody drugs and digital factory construction - The total investment for these projects is RMB 335,433.49 million, with RMB 318,275.95 million allocated to the new drug research project and RMB 163,442.82 million to the industrialization project [3][4]. Fund Usage and Surplus - As of August 29, 2025, the company has completed the investment commitments for the aforementioned projects, with a total of RMB 163,733.77 million utilized, resulting in a surplus of RMB 7,029.08 million [4][6]. - The surplus funds will be permanently supplemented into the company's working capital to enhance cash flow and economic efficiency [6]. Approval Process - The board of directors and the supervisory board approved the decision to use the surplus funds, stating it would improve fund utilization efficiency and align with the company's development strategy [6][7]. - The sponsor institution confirmed that the process followed necessary legal procedures and complied with relevant regulations, ensuring no adverse impact on the company's operations [7][8].

Core Points - The board of directors of Yiyang Xintong Co., Ltd. held its 21st meeting of the 9th session, where several key resolutions were passed [1][2][3][4]. Group 1: Financial Reports - The board approved the "Yiyang Xintong 2025 Semi-Annual Report and Summary," which was reviewed by the audit committee before submission [1]. - A special report on the management and actual use of the raised funds for the first half of 2025 was also approved [2]. Group 2: Employee Stock Ownership Plans - The board approved the extension of the first phase of the employee stock ownership plan for 2015, with 7 votes in favor [2]. - Similarly, the extension of the first phase of the employee stock ownership plan for 2016 was approved, also with 7 votes in favor [2]. Group 3: Fund Management and Governance Changes - The board approved a proposal to terminate certain fundraising investment projects and use the remaining funds to permanently supplement working capital, requiring approval at the next shareholders' meeting [3]. - A resolution to cancel the supervisory board and amend the company's articles of association and related rules was passed, also requiring approval at the next shareholders' meeting [3][4]. - The board approved the revision of the "Implementation Rules of the Board of Directors Audit Committee" [4]. Group 4: Upcoming Meetings - The board announced the convening of the second extraordinary shareholders' meeting of 2025, scheduled for September 15, 2025, at 14:30 [4].

截 至 2025 年 6 月 30 日 ， 公 司 累 计 使 用 募 集 配 套 资 金 合 计 人 民 币 包括募集资金银行账户利息收入及尚未支付的发行费用。 国泰海通证券股份有限公司 关于 2025 年半年度募集资金存放、管理与实际使用 情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》及《上海证券 交易所上市公司自律监管指引第 1 号——规范运作》的规定，国泰海通证券股份 有限公司（以下简称公司）编制了截至 2025 年 6 月 30 日公司募集资金存放、管 理与实际使用情况的专项报告。具体如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意国泰君安证券股份有限公司吸收合并 海通证券股份有限公司并募集配套资金注册、核准国泰君安证券股份有限公司吸 收合并海通证券股份有限公司、海富通基金管理有限公司变更主要股东及实际控 制人、富国基金管理有限公司变更主要股东、海通期货股份有限公司变更主要股 东及实际控制人的批复》（证监许可〔2025〕96 号） ...